These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 3308076)
41. PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Solbach C; Roller M; Fellbaum C; Nicoletti M; Kaufmann M Breast; 2004 Feb; 13(1):80-1. PubMed ID: 14759723 [TBL] [Abstract][Full Text] [Related]
42. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Tanaka T; Slamon DJ; Shimoda H; Waki C; Kawaguchi Y; Tanaka Y; Ida N Cancer Res; 1988 Feb; 48(4):1030-4. PubMed ID: 3276397 [TBL] [Abstract][Full Text] [Related]
43. ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues. Thor A; Ohuchi N; Hand PH; Callahan R; Weeks MO; Theillet C; Lidereau R; Escot C; Page DL; Vilasi V Lab Invest; 1986 Dec; 55(6):603-15. PubMed ID: 2431221 [No Abstract] [Full Text] [Related]
44. Expression of p21 ras gene products in breast cancer relates to histological types and to receptor and nodal status. Querzoli P; Marchetti E; Bagni A; Marzola A; Fabris G; Nenci I Breast Cancer Res Treat; 1988 Sep; 12(1):23-30. PubMed ID: 3058236 [TBL] [Abstract][Full Text] [Related]
45. [Expression of p21ras in tumors of breast]. Catozzi L; Faggioli L; Giovannini G; Dati C; Pelizzola D; Piffanelli A Boll Soc Ital Biol Sper; 1988 Oct; 64(10):945-52. PubMed ID: 3077333 [No Abstract] [Full Text] [Related]
46. The H-ras oncogene product p21 and prognosis in human breast cancer. Watson DM; Elton RA; Jack WJ; Dixon JM; Chetty U; Miller WR Breast Cancer Res Treat; 1991; 17(3):161-9. PubMed ID: 2039838 [TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical detection of H-ras protooncoprotein p21 indicates favorable prognosis in node-negative breast cancer patients. Göhring UJ; Schöndorf T; Kiecker VR; Becker M; Kurbacher C; Scharl A Tumour Biol; 1999; 20(4):173-83. PubMed ID: 10393527 [TBL] [Abstract][Full Text] [Related]
48. ras p21 expression in the progression of breast cancer. Fromowitz FB; Viola MV; Chao S; Oravez S; Mishriki Y; Finkel G; Grimson R; Lundy J Hum Pathol; 1987 Dec; 18(12):1268-75. PubMed ID: 3315956 [TBL] [Abstract][Full Text] [Related]
49. Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. Sumiya H; Masai M; Akimoto S; Yatani R; Shimazaki J Eur J Cancer; 1990; 26(7):786-9. PubMed ID: 1699574 [TBL] [Abstract][Full Text] [Related]
50. Association between the ras p21 oncoprotein in blood samples and breast cancer. Rundle A; Tang D; Brandt-Rauf P; Zhou J; Kelly A; Schnabel F; Perera FP Cancer Lett; 2002 Nov; 185(1):71-8. PubMed ID: 12142081 [TBL] [Abstract][Full Text] [Related]
51. Comparative study of Harvey-ras oncogene expression with conventional clinicopathologic parameters of breast cancer. Agnantis NJ; Parissi P; Anagnostakis D; Spandidos DA Oncology; 1986; 43(1):36-9. PubMed ID: 2417178 [TBL] [Abstract][Full Text] [Related]
52. Co-expression and significance of Dok2 and Ras p21 protein activator 1 in breast cancer. Huang J; Peng X; Zhang K; Li C; Su B; Zhang Y; Yu W Oncol Lett; 2017 Nov; 14(5):5386-5392. PubMed ID: 29098030 [TBL] [Abstract][Full Text] [Related]
53. ras p21 expression in the progression of breast cancer. Williams AR; Piris J; Wyllie AH Hum Pathol; 1988 Sep; 19(9):1115. PubMed ID: 3047053 [No Abstract] [Full Text] [Related]
54. Molecular biology of breast carcinoma. el-Ashry D; Lippman ME World J Surg; 1994; 18(1):12-20. PubMed ID: 8197767 [TBL] [Abstract][Full Text] [Related]
55. Estrogen and breast cancer: can less mean more? Bullock MD; Silva AM; Calin GA Cell Cycle; 2015; 14(14):2197-8. PubMed ID: 26090587 [No Abstract] [Full Text] [Related]
56. Loss of RAB25 Cooperates with Oncogenes in the Transformation of Human Mammary Epithelial Cells (HMECs) to Give Rise to Claudin-Low Tumors. Joshi P; Ayyagari V; Kandel S; Modur V; Iqbal MF; Robinson K; Gao J; Rao K Biomed Res Int; 2024; 2024():8544837. PubMed ID: 38803515 [TBL] [Abstract][Full Text] [Related]
57. Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion. Collins SE; Wiegand ME; Werner AN; Brown IN; Mundo MI; Swango DJ; Mouneimne G; Charest PG Mol Biol Cell; 2023 Feb; 34(2):ar9. PubMed ID: 36542482 [TBL] [Abstract][Full Text] [Related]
58. Global Signaling Profiling in a Human Model of Tumorigenic Progression Indicates a Role for Alternative RNA Splicing in Cellular Reprogramming. Caruso JA; Carruthers NJ; Thibodeau B; Geddes TJ; Dombkowski AA; Stemmer PM Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30241319 [TBL] [Abstract][Full Text] [Related]
59. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347 [TBL] [Abstract][Full Text] [Related]
60. Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation. Lee KH; Koh M; Moon A Oncol Lett; 2016 Sep; 12(3):2222-2226. PubMed ID: 27602167 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]